Azelaic Acid 16% | Niacinamide 4%

Applied topically as a thin, even layer to the affected area(s) per prescriber direction:

• Cleanse and dry the skin before application.
• Apply a thin layer and gently massage until absorbed; avoid mucous membranes, eyes, and lips.
• Wash hands before and after use.
• Sunscreen (SPF 30+) is recommended during daytime use to optimize hyperpigmentation outcomes and prevent UV-driven pigmentation recurrence.

Dosing frequency is prescriber-determined. General principles based on the established pharmacology of each ingredient:

• Azelaic acid 15% is typically applied twice daily in FDA-approved formulations (Finacea 15% gel, Azelex 20% cream); the 16% compounded strength follows comparable dosing guidance.
• Niacinamide 4% is generally well-tolerated for twice-daily application.
• The prescriber will specify frequency (typically once or twice daily) and treatment duration based on diagnosis, skin type, and response.
• Reassess response at 4–8 week intervals; adjust as clinically indicated.

• Azelaic Acid: Inhibits microbial protein synthesis in Cutibacterium acnes (antimicrobial); reversibly inhibits several mitochondrial oxidoreductases (thioredoxin reductase, mitochondrial respiratory chain enzymes), reducing reactive oxygen species production by activated neutrophils and abnormal melanocytes; inhibits tyrosinase selectively in hyperactive melanocytes; normalizes keratinization by reducing stratum corneum thickness and keratohyalin granule formation.
• Niacinamide: Interferes with the paracrine signaling between melanocytes and keratinocytes that normally facilitates melanosome transfer; niacinamide does not inhibit tyrosinase or melanin synthesis directly but reduces the loading of melanin-containing melanosomes into keratinocytes. It also suppresses pro-inflammatory cytokines (TNF-α, IL-1β) in keratinocytes, reduces sebaceous lipid production, and may improve skin barrier function.

This dual-agent formulation is prescribed for the prescriber-directed management of acne vulgaris, rosacea, post-inflammatory hyperpigmentation (PIH), and conditions requiring combined anti-inflammatory and depigmenting topical therapy. Clinical considerations:

• Azelaic acid 15% is FDA-approved for both rosacea and acne; the 16% compounded strength is a slight adjustment from the commercial norm and requires prescriber documentation of clinical rationale.
• Niacinamide's distinct mechanism (melanosome transfer inhibition vs. tyrosinase inhibition) is complementary to azelaic acid; together they address different steps in the melanin-delivery pathway.
• Both ingredients are generally well-tolerated on sensitive and rosacea-prone skin; the combination avoids the irritant potential of retinoids or high-concentration hydroquinone.
• Niacinamide 4% is within the clinically studied range (2–5%) for hyperpigmentation; side effects are rare at this concentration.
• Follow-up at 4–8 weeks to assess acne or PIH response; reinforce sun protection as an essential component of any hyperpigmentation regimen.

Contraindications:

• Hypersensitivity to azelaic acid, niacinamide, or any formulation component.

Warnings & Precautions:

• Azelaic acid: transient stinging, burning, and pruritus are common, particularly during the first weeks of use and on sensitized skin.
• Niacinamide: topical side effects are rare; high oral doses (not applicable here topically) are associated with flushing, but topical application at 4% does not cause systemic niacin-flush syndrome.
• Avoid contact with eyes, nostrils, and lips.
• Discontinue if severe contact dermatitis or persistent worsening occurs and notify the prescriber.

Drug Interactions:

• Concurrent use with other azelaic acid formulations or strong keratolytics may increase local irritation.

Common Side Effects: Transient stinging, burning, or pruritus at the application site (primarily azelaic acid); mild erythema; rare contact dermatitis. Niacinamide topical side effects are uncommon at 4%.

Store at controlled room temperature (15–25°C / 59–77°F) in the original container. Protect from heat, light, and moisture. Do not freeze. Keep out of reach of children. Use by the beyond-use date (BUD) per USP <795> compounding standards. Discard if the product changes color, consistency, or develops an unusual odor.

Is this formulation FDA-approved?

No. This is a patient-specific, prescriber-directed 503A compounded preparation from Genesis Compounding. While azelaic acid has FDA-approved commercial formulations at 15% and 20%, this compounded combination at the specified concentrations is not FDA-approved.

How does niacinamide differ from azelaic acid for hyperpigmentation?

Azelaic acid inhibits tyrosinase in hyperactive melanocytes, reducing melanin synthesis. Niacinamide does not inhibit tyrosinase; instead it prevents finished melanosomes from being transferred from melanocytes into surrounding keratinocytes. Together they interrupt two different steps in the pigment-delivery process.

Is this safe for sensitive or rosacea-prone skin?

Both ingredients are generally considered well-tolerated on sensitive skin. Azelaic acid is widely used for rosacea, and niacinamide is noted for its skin-tolerability profile. Some initial stinging from azelaic acid is expected and typically subsides with continued use.

Do I need sunscreen with this preparation?

Yes. UV exposure can reverse pigmentation gains and stimulate melanogenesis. Daily broad-spectrum sunscreen (SPF 30+) is an important adjunct to any topical depigmenting regimen.

When can I expect to see improvement?

Improvement in inflammatory lesion counts (acne/rosacea) may begin within 4–6 weeks. Visible reduction in post-inflammatory hyperpigmentation typically requires 8–12 weeks of consistent application combined with photoprotection. Your prescriber will reassess response at follow-up.